Positioning of proteasome inhibitors in therapy of solid malignancies

Margot S.F. Roeten, Jacqueline Cloos*, Gerrit Jansen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Targeting of the protein degradation pathway, in particular, the ubiquitin-proteasome system, has emerged as an attractive novel cancer chemotherapeutic modality. Although proteasome inhibitors have been most successfully applied in the treatment of hematological malignancies, they also received continuing interest for the treatment of solid tumors. In this review, we summarize the current positioning of proteasome inhibitors in the treatment of common solid malignancies (e.g., lung, colon, pancreas, breast, and head and neck cancer), addressing topics of their mechanism(s) of action, predictive factors and molecular mechanisms of resistance.

Original languageEnglish
Pages (from-to)227-243
Number of pages17
JournalCancer Chemotherapy and Pharmacology
Issue number2
Publication statusPublished - 1 Feb 2018

Cite this